表紙:世界の血管閉塞デバイス市場予測(2021年~2026年)
市場調査レポート
商品コード
1023144

世界の血管閉塞デバイス市場予測(2021年~2026年)

Global Vascular Closure Devices (VCDs) Market - Forecasts from 2021 to 2026

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.26円
世界の血管閉塞デバイス市場予測(2021年~2026年)
出版日: 2021年10月05日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の血管閉塞デバイス市場規模は、2019年に17億2,300万米ドルに達しました。2026年には27億4,400万米ドルに達すると予測され、今後、市場は、2019年から2026年の予測期間中に6.88%のCAGRで成長すると予測されています。

当レポートでは、世界の血管閉塞デバイス市場について調査しており、市場力学、市場分析、競合環境と分析、企業プロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 仮定

第3章 エグゼクティブサマリー

  • 調査のハイライト

第4章 市場力学

  • 市場の推進力
  • 市場の抑制要因
  • ポーターのファイブフォース分析
    • サプライヤの交渉力
    • 買い手の交渉力
    • 新規参入企業の脅威
    • 代替品の脅威
    • 機能における競争企業間の敵対関係
  • 機能バリューチェーン分析

第5章 世界の血管閉鎖デバイス(VCD)市場分析:アクセス別

  • イントロダクション
  • 大腿骨
  • 橈骨

第6章 世界の血管閉鎖デバイス(VCD)市場分析:タイプ別

  • イントロダクション
  • パッシブ血管閉鎖デバイス
  • アクティブ血管閉鎖デバイス

第7章 世界の血管閉鎖デバイス(VCD)市場分析:エンドユーザー別

  • イントロダクション
  • 病院およびクリニック
  • 外来手術センター

第8章 世界の血管閉鎖デバイス(VCD)市場分析:手順別

  • イントロダクション
  • 心血管インターベンション
  • 画像下治療/血管手術

第9章 世界の血管閉鎖デバイス(VCD)市場分析:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • その他
  • 中東およびアフリカ
    • イスラエル
    • サウジアラビア
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • 台湾
    • タイ
    • インドネシア
    • その他

第10章 競合環境と分析

  • 主要企業と戦略分析
  • 新興企業と市場の収益性
  • 合併、買収、合意、および協業
  • ベンダー競争力マトリックス

第11章 企業プロファイル

  • Medtronic
  • Terumo
  • Abbott
  • Cordis
  • Biomerics
  • Cardiva Medical, Inc.
  • Vasorum Ltd
  • Biotronik GMBH & CO.KG
  • Boston Scientific Corporation
  • TZ Medical, Inc
目次
Product Code: KSI061611748

The global vascular closure devices (VCDs) market is projected to grow at a CAGR of 6.88% to reach US$2.744 billion by 2026, from US$1.723 billion in 2019.

Vascular closure devices (VCDs) are medical devices that are used to seal punctures in the femoral artery in patients who have had diagnostic or interventional angiography operations. The growing popularity of VCDs is due to the fact that they are a viable alternative to manual compression, which is a time-consuming operation that varies based on the size of the plastic sheath inserted into the artery. Mechanical or manual compression does not provide rapid closure of the femoral artery entry point, as VCDs do. The rising popularity of femoral artery cardiac catheterization, the high success rate of VCDs for better patient comfort, and the reduction of hemostasis time are all aspects that might contribute to the market's anticipated expansion during the forecast period. Throughout the projection period, VCD use for diagnostic and therapeutic treatments that allow endovascular image-guided interventions to identify coronary heart disease is projected to contribute to the market's growth. Furthermore, VCDs' capacity to overcome problems such prolonged bed rest and patient pain due by manual compression is projected to enhance industry growth during the projection period. The development of VCDs has transformed the landscape of cardiovascular operations due to ongoing improvements in medical technology. The development of vascular closure devices aids in the prevention of problems related to the vascular access site, which is the leading source of morbidity during catheterization operations. VCDs also decrease the time it takes to achieve hemostasis and increase patient comfort, which has boosted market development expectations.

The existence of significant players operating in this area, as well as an established healthcare system, are factors linked to the rise of vascular closure devices in North America. The North American area offers a diverse range of growth prospects, which is drawing new vascular closure investors. The growing incidence of lifestyle illnesses, government attempts to create breakthrough technology, and demand for advanced medical services are all contributing to the industry's growth. Furthermore, rising rates of cardiovascular disease in the United States are likely to boost VCD use in the area. However, due to the developing economies of China and India, Asia Pacific is anticipated to grow at the highest rate in recent years. Furthermore, the availability of unexplored areas and unmet patient requirements has piqued the interest of industry participants, and they are potential development drivers in this region. Key businesses in many areas are expanding their product portfolios in order to get access to previously unexplored markets, resulting in increased growth in this sector.

Growth Factors

The majority of interventional procedures use femoral mode for vascular access fueling the market growth.

One of the major reasons for the growth of the global vascular closure devices market is the use of femoral mode for vascular access. In general, the femoral mode is used for vascular access during coronary angiography and other interventional procedures. The fragment will notice dramatic development since femoral veins are considerably less inclined to fit in association with outspread and offer large-size catheters. Furthermore, the improvement of specific devices that provide access to the femoral blood artery improves fragment extension capacities. However, a few issues with the femoral access site, such as arteriovenous (AV) fistula, pseudoaneurysm, and blood vessel analysis, limit acceptance to a certain extent. As a result of these characteristics, as well as the high procedural volume, the section is expected to grow powerfully during the figure timetable. Furthermore, in the vascular closure devices market, specialty-focused solutions are gaining traction. For example, Teleflex, a major provider of specialty medical devices for critical care and surgery, has announced that its MANTA vascular closure device would be demonstrated at the 2019 PCR London Valves, a multi-disciplinary course being conducted in London, United Kingdom. Specialty-focused solutions are assisting healthcare practitioners throughout the world in improving patient health and quality of life. Companies are putting more effort into developing solutions that simplify difficult procedures and eliminate obstacles associated with typical procedural issues, which is likely to drive market growth even further.

Restraints

The rising use of radial access for interventional procedures, the high cost of vascular closure devices, and the hazards associated with vascular closure devices are all key market constraints.

A major restraint in the growth of the global vascular closure devices (VCDs) market is the rising use of radial access for interventional procedures, the high cost of vascular closure devices, and the hazards associated with vascular closure devices. When compared to manual compression devices, vascular closure devices are more expensive. The cost of VCDs is basically added to the patient's hospital bill, and it even raises the per-patient cost for hospitals, reducing revenues at the same time. Furthermore, having access to the radial artery makes it easier for clinicians to accomplish hemostasis utilizing simple manual compression techniques. Another element that contributes to cost savings is the absence of vascular closure devices in interventional procedures employing radial artery access. Furthermore, gadget malfunctions, poor quality, and underperformance are the leading reasons of product recalls. Product failures and recalls cost businesses millions of dollars in lost revenue and product replacements. They may also leave an unfavorable image of the product, which may restrict its adoption.

Impact of COVID-19

The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. During the underlying period of pandemics, the development of COVID-19 had an impact on the procedure volume of a few cardiovascular medications. Due of the high risk of Covid contamination during such methods, as well as the growing number of COVID-19 patients admitted to hospitals, the technique was postponed. Nonetheless, the industry is expected to see continued expansion with conventional operating norms and a reduction in the number of patients in specific countries. Mechanical revenue growth has also been aided by authoritative collaborative efforts and government assistance to continue providing successful crisis cardiac treatment to patients. Despite the fact that the market has had a mild influence for a while, it continues to forecast massive growth. However, in the post COVID scenario the global vascular closure devices market is expected to bloom with the surging demand in the forecast period.

Competitive Insights

The market leaders for the pretreatment coating market are Medtronic, Terumo, Abbott, Cordis, Biomerics, Cardiva Medical, Inc., Vasorum Ltd, Biotronik GMBH & CO.KG, Boston Scientific Corporation, and TZ Medical, Inc.

Segmentation:

By Access

  • Femoral Access
  • Radial Access

By Type

  • Passive Vascular Closure Devices
  • Active Vascular Closure Devices

By End-Users

  • Hospitals & Clinics
  • Ambulatory Surgical Centres

By Procedure

  • Interventional Vascular Surgery
  • Interventional Cardiology

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Indonesia
    • Taiwan
    • Thailand
    • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Function
  • 4.4. Function Value Chain Analysis

5. Global Vascular Closure Devices (VCDs) Market Analysis, By Access

  • 5.1. Introduction
  • 5.2. Femoral Access
  • 5.3. Radial Access

6. Global Vascular Closure Devices (VCDs) Market Analysis, By Type

  • 6.1. Introduction
  • 6.2. Passive Vascular Closure Devices
  • 6.3. Active Vascular Closure Devices

7. Global Vascular Closure Devices (VCDs) Market Analysis, By End-Users

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Ambulatory Surgical Centers

8. Global Vascular Closure Devices (VCDs) Market Analysis, By Procedure

  • 8.1. Introduction
  • 8.2. Interventional Cardiology
  • 8.3. Interventional Radiology/Vascular Surgery

9. Global Vascular Closure Devices (VCDs) Market Analysis, By Geography

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. UK
    • 9.4.2. Germany
    • 9.4.3. Italy
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Israel
    • 9.5.2. Saudi Arabia
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. Japan
    • 9.6.3. India
    • 9.6.4. Australia
    • 9.6.5. South Korea
    • 9.6.6. Taiwan
    • 9.6.7. Thailand
    • 9.6.8. Indonesia
    • 9.6.9. Others

10. Competitive Environment and Analysis

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativeness
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. Company Profiles

  • 11.1. Medtronic
  • 11.2. Terumo
  • 11.3. Abbott
  • 11.4. Cordis
  • 11.5. Biomerics
  • 11.6. Cardiva Medical, Inc.
  • 11.7. Vasorum Ltd
  • 11.8. Biotronik GMBH & CO.KG
  • 11.9. Boston Scientific Corporation
  • 11.10. TZ Medical, Inc